(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 January 2020 (09.01.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/010196 A1

(51) International Patent Classification:
A61K 9/00 (2006.01) *A61K 47/02* (2006.01)
A61K 31/4439 (2006.01) *A61K 47/40* (2006.01)
A61K 31/5415 (2006.01) *A61P 25/06* (2006.01)

(21) International Application Number:
PCT/US2019/040495

(22) International Filing Date:
03 July 2019 (03.07.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/693,871	03 July 2018 (03.07.2018)	US
62/802,198	06 February 2019 (06.02.2019)	US
62/803,756	11 February 2019 (11.02.2019)	US
62/835,613	18 April 2019 (18.04.2019)	US
62/846,311	10 May 2019 (10.05.2019)	US
62/860,705	12 June 2019 (12.06.2019)	US

(71) Applicant: **AXSOME THERAPEUTICS, INC.** [US/US]; 200 Broadway, 3rd Floor, New York, NY 10038 (US).

(72) Inventor: **TABUTEAU, Herriot**; 200 Broadway, 3rd Floor, New York, NY 10038 (US).

(74) Agent: **JOHNSON, Brent, A.** et al.; Maschoff Brennan, 100 Spectrum Center Drive, Suite 1200, Irvine, CA 92618 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING MELOXICAM

(57) Abstract: Disclosed herein are compositions comprising a drug such as a triptan (e.g. rizatriptan) and/or an NSAID (e.g. meloxicam) in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability, solubility, or pharmacokinetics of the drug for the treatment of conditions such as pain.

WO 2020/010196 A1